Related Experiment Video
Updated: Sep 27, 2025

Establishing a Competing Risk Regression Nomogram Model for Survival Data
Published on: October 23, 2020
Risk Scoring System for Ra-223 Discontinuation and Its Effect on Prognosis: A Retrospective Study
Hitoshi Ito1, Hiroshi Yaegashi2, Yoshiyuki Okada3
1Department of Radiation Oncology, Kyoto Katsura Hospital, Kyoto, Japan.
Background/Aim:
Radium-223 therapy prolongs overall survival in castration-resistant prostate cancer (CRPC) patients with bone metastasis. Patients who are unable to complete six courses of radium-223 therapy reportedly have a poor prognosis. This study aimed to develop a risk score using the discontinuation factors of the above therapy modality.
Patients And Methods:
Seventy patients who received radium-223 therapy for metastatic CRPC at two Japanese Institutions were evaluated. Univariate and multivariate analyses were performed to identify the discontinuation factors and determine the risk scores.
Results:
The median survival time was 24.3 and 9.5 months in patients who did and did not complete the therapy, respectively. Multivariate analysis revealed haemoglobin and prostate-specific antigen as key factors. A risk score was developed using these factors, and patients were stratified into three groups. The discontinuation rate and survival after radium-223 therapy were significantly different.
Conclusion:
Our risk score may help evaluate the suitability of radium-223 in CRPC patients.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Relative Risk
Actuarial Approach
Consider the example of a high-risk surgical procedure with significant early-stage mortality. A two-year clinical study is conducted,...
Assumptions of Survival Analysis
Comparing the Survival Analysis of Two or More Groups

